OptiNose (OptiNose) Forward Dividend Yield % : 0.00% (As of May. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is OptiNose Forward Dividend Yield %?

As of today (2024-05-28), the Forward Annual Dividend Yield of OptiNose is 0.00%.

As of today (2024-05-28), the Trailing Annual Dividend Yield of OptiNose is 0.00%.

OPTN's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.875
* Ranked among companies with meaningful Forward Dividend Yield % only.

OptiNose's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of OptiNose's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptiNose's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where OptiNose's Forward Dividend Yield % falls into.

OptiNose Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

OptiNose (NAS:OPTN) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

OptiNose Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of OptiNose's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose (OptiNose) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

0OP:Germany

Address

1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067

Website

https://www.optinose.com

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

Executives

Marino Michael F Iii	officer: Chief Legal Officer & Corp Sec	C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud	officer: President & COO	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller	director, officer: Chief Executive Officer	C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis	officer: Acting Chief Financial Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli	officer: Chief Commercial Officer	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence	officer: Chief Commercial Officer	1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick	officer: Chief Accounting Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080